NEWS&EVENTS

BACK TO LIST
June 25, 2022 The 2nd CHANCE Investigator Meeting brings together investigators around the globe to share their insights on project progress The 2nd CHANCE Investigator Meeting took place on 24 June 2022 in London, UK

LONDON—The 2nd CHANCE Investigator Meeting took place in London, UK, during the celebration of the International Liver Congress 2022 organized by the European Association for the Study of the Liver (EASL). This event brought together 49 investigators and professionals from 18 countries (Argentina, Belgium, Brazil, Czech Republic, France, Germany, India, Italy, Japan, Poland, South Korea, Spain, Switzerland, Taiwan, The Netherlands, Turkey, UK and USA), 27 people attended in person and 22 joined online.

Regional coordinators Vinay Sundaram for North America, Sebastian Marciano for Latin America, Mohamed Rela for India, and Rachel Westbrook for UK presented an overview of recruitment progress up to date and shared their insights into overcoming major challenges regarding patient recruitment, ethical and budgetary issues.

Thierry Gustot presented the current status in European sites and the first results from the CHANCE study and Anna Bosch, General Manager of EF Clif, explained the procedure for submitting ancillary study proposals and how we continue making efforts to strengthen communication among participating centers and collaborators to maximize the impact of the results that will derived from this study.

The CHANCE study is promoted by EF Clif.

About the CHANCE study

CHANCE is a multicenter, global, observational study designed to assess the benefit of liver transplantation in patients with acute-on-chronic liver failure (ACLF) grade 2 or grade 3. This study counts with the support of the International Liver Transplantation Society (ILTS) and the European Liver and Intestine Transplant Association (ELITA) to recruit 2000 patients in 80 centers in 27 countries around the world. The primary objective of the CHANCE study is to compare 1-year graft and patient survival rates after liver transplantation in patients with ACLF grade 2 or grade 3 at the time of liver transplantation with patients with decompensation of cirrhosis without ACLF-2 or 3 and transplant-free survival of patients with ACLF-2 or 3 not listed for liver transplantation. The international nature of this study will allow for deep assessments of the potential impact of different precipitating factors of ACLF (e.g., alcohol vs. Hepatitis B virus flare), different types of liver transplantation (deceased donor vs. living donor liver transplantation) and different regional and national allocation systems on transplant outcomes. Beside these clinical objectives, the CHANCE study aims to build a repository of biological samples to explore new biomarkers to predict prognosis on the waiting list and after liver transplantation, and mechanisms of liver and extrahepatic organ recovery.

ClinicalTrials.gov Identifier: NCT04613921


About EF Clif

The European Foundation for the Study of Chronic Liver Failure (EF Clif) is a private nonprofit organization which mission is to promote research and education in hepatic chronic failure with the aim to contribute to improving the quality of life and to increase the survival of patients with liver cirrhosis. Since its foundation in 2009, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL-Clif Consortium, a network of more than 100 European university hospitals and more than 300 clinical researchers. The Grifols Chair promotes translational studies across centers throughout Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers and more than 40 investigators.

BACK TO LIST